RU2018143810A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2018143810A3 RU2018143810A3 RU2018143810A RU2018143810A RU2018143810A3 RU 2018143810 A3 RU2018143810 A3 RU 2018143810A3 RU 2018143810 A RU2018143810 A RU 2018143810A RU 2018143810 A RU2018143810 A RU 2018143810A RU 2018143810 A3 RU2018143810 A3 RU 2018143810A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
- C12N2830/205—Vector systems having a special element relevant for transcription transcription of more than one cistron bidirectional
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16169284.3 | 2016-05-12 | ||
EP16169284 | 2016-05-12 | ||
PCT/EP2017/061282 WO2017194655A1 (en) | 2016-05-12 | 2017-05-11 | Potent and balanced bidirectional promoter |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2018143810A RU2018143810A (ru) | 2020-06-15 |
RU2018143810A3 true RU2018143810A3 (ru) | 2020-10-09 |
RU2758238C2 RU2758238C2 (ru) | 2021-10-26 |
Family
ID=56026656
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2018143810A RU2758238C2 (ru) | 2016-05-12 | 2017-05-11 | Эффективный и сбалансированный двунаправленный промотор |
Country Status (14)
Country | Link |
---|---|
US (2) | US11473105B2 (ru) |
EP (1) | EP3455358B1 (ru) |
JP (1) | JP7046835B2 (ru) |
KR (1) | KR102573534B1 (ru) |
CN (1) | CN109154000B (ru) |
AU (1) | AU2017264562B2 (ru) |
BR (1) | BR112018072865A2 (ru) |
CA (1) | CA3023322A1 (ru) |
ES (1) | ES2829272T3 (ru) |
IL (1) | IL262876A (ru) |
MX (1) | MX2018013817A (ru) |
RU (1) | RU2758238C2 (ru) |
WO (1) | WO2017194655A1 (ru) |
ZA (1) | ZA201807542B (ru) |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0173552B1 (en) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Recombinant dna compounds and the expression of polypeptides such as tpa |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
AU629554B2 (en) * | 1988-06-24 | 1992-10-08 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Exogenous gene expression vector containing chick beta-actin gene promoter |
FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
WO1995034671A1 (en) | 1994-06-10 | 1995-12-21 | Genvec, Inc. | Complementary adenoviral vector systems and cell lines |
US5559099A (en) | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
US5965541A (en) | 1995-11-28 | 1999-10-12 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
US5837520A (en) | 1995-03-07 | 1998-11-17 | Canji, Inc. | Method of purification of viral vectors |
ATE445705T1 (de) | 1995-06-15 | 2009-10-15 | Crucell Holland Bv | Verpackungssysteme für humane rekombinante adenoviren zur gentherapie |
US5837511A (en) | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
US5891690A (en) | 1996-04-26 | 1999-04-06 | Massie; Bernard | Adenovirus E1-complementing cell lines |
CZ438398A3 (cs) | 1996-07-01 | 1999-03-17 | Rhone-Poulenc Rorer S. A. | Způsob přípravy rekombinantních adenovirů |
FR2751343B1 (fr) | 1996-07-16 | 1998-12-18 | Transgene Sa | Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament |
WO1998010087A1 (en) | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
US6261823B1 (en) | 1996-12-13 | 2001-07-17 | Schering Corporation | Methods for purifying viruses |
US6020191A (en) | 1997-04-14 | 2000-02-01 | Genzyme Corporation | Adenoviral vectors capable of facilitating increased persistence of transgene expression |
US5981225A (en) | 1998-04-16 | 1999-11-09 | Baylor College Of Medicine | Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same |
US6113913A (en) | 1998-06-26 | 2000-09-05 | Genvec, Inc. | Recombinant adenovirus |
US6225289B1 (en) | 1998-12-10 | 2001-05-01 | Genvec, Inc. | Methods and compositions for preserving adenoviral vectors |
DE19955558C2 (de) | 1999-11-18 | 2003-03-20 | Stefan Kochanek | Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren |
CA2419790A1 (en) * | 2000-08-18 | 2002-02-21 | Gencell S.A. | System for regulating in vivo the expression of a transgene by conditional inhibition |
JP4550421B2 (ja) | 2001-12-12 | 2010-09-22 | メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド | ウイルスの保存のための組成物 |
BR0306925A (pt) | 2002-01-18 | 2004-11-09 | Schering Ag | Formulações estabilizadas de adenovìrus |
US20030180936A1 (en) | 2002-03-15 | 2003-09-25 | Memarzadeh Bahram Eric | Method for the purification, production and formulation of oncolytic adenoviruses |
IL164802A0 (en) | 2002-04-25 | 2005-12-18 | Crucell Holland Bv | Stable adenoviral vectors and methods for propagation thereof |
IL164803A0 (en) | 2002-04-25 | 2005-12-18 | Crucell Holland Bv | Means and methods for the production of adenovirusvectors |
ATE360683T1 (de) | 2002-05-14 | 2007-05-15 | Merck & Co Inc | Verfahren zur reinigung von adenovirus |
SE0202110D0 (sv) | 2002-07-05 | 2002-07-05 | Isconova Ab | Iscom preparation and use thereof |
EP1585964A4 (en) | 2002-08-28 | 2008-07-16 | Introgen Therapeutics Inc | CHROMATOGRAPHIC METHODS FOR PURIFYING ADENOVIRUSES |
WO2004037294A2 (en) | 2002-10-23 | 2004-05-06 | Crucell Holland B.V. | New settings for recombinant adenoviral-based vaccines |
WO2004055187A1 (en) | 2002-12-17 | 2004-07-01 | Crucell Holland B.V. | Recombinant viral-based malaria vaccines |
EP1601776B1 (en) * | 2003-03-11 | 2008-07-02 | Laboratoires Serono SA | Expression vectors comprising the mcmv ie2 promoter |
SE0301998D0 (sv) | 2003-07-07 | 2003-07-07 | Isconova Ab | Quil A fraction with low toxicity and use thereof |
CN102719478A (zh) | 2004-01-23 | 2012-10-10 | P.安杰莱蒂分子生物学研究所 | 黑猩猩腺病毒疫苗载运体 |
CA2555412C (en) | 2004-02-23 | 2013-06-25 | Crucell Holland B.V. | Virus purification methods |
WO2006053871A2 (en) | 2004-11-16 | 2006-05-26 | Crucell Holland B.V. | Multivalent vaccines comprising recombinant viral vectors |
US8574595B2 (en) | 2005-04-11 | 2013-11-05 | Crucell Holland B.V. | Virus purification using ultrafiltration |
JP5175178B2 (ja) | 2005-05-12 | 2013-04-03 | グラクソ グループ リミテッド | ワクチン組成物 |
CN101384902A (zh) | 2005-12-16 | 2009-03-11 | Uab研究基金会 | 与使用病毒载体控制的基因表达相关的组合物和方法 |
US7879602B2 (en) | 2006-02-28 | 2011-02-01 | Vaxart, Inc. | Chimeric adenoviral vectors |
US20100143302A1 (en) | 2006-03-16 | 2010-06-10 | Crucell Holland B.V. | Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof |
US20090110695A1 (en) | 2006-03-27 | 2009-04-30 | Menzo Jans Emko Havenga | Compositions Comprising a Recombinant Adenovirus and an Adjuvant |
WO2009026183A1 (en) | 2007-08-17 | 2009-02-26 | The Government Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services | Use of chimeric hiv/siv gag proteins to optimize vaccine-induced t cell responses against hiv gag |
WO2009117134A2 (en) | 2008-03-21 | 2009-09-24 | National Institutes Of Health | Aerosolized genetic vaccines and methods of use |
AU2009279334B2 (en) * | 2008-08-07 | 2014-07-10 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health | Optimized promoter sequence |
WO2010085984A1 (en) | 2009-02-02 | 2010-08-05 | Okairos Ag | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
EP3385387B1 (en) | 2009-02-02 | 2021-08-25 | GlaxoSmithKline Biologicals SA | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
WO2010096561A1 (en) | 2009-02-18 | 2010-08-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Synthetic hiv/siv gag proteins and uses thereof |
DK2488635T3 (en) | 2009-10-15 | 2014-02-24 | Crucell Holland Bv | A method for purifying adenovirus of cultures with high cell density |
BR112012008516B1 (pt) | 2009-10-15 | 2021-10-19 | Janssen Vaccines & Prevention B.V. | Método para purificar partículas de adenovírus a partir de uma suspensão de célula |
JP5770952B2 (ja) * | 2012-03-12 | 2015-08-26 | クルセル ホランド ベー ヴェー | 改変末端を有する組換えアデノウイルスのバッチ |
US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
MY169352A (en) | 2012-03-22 | 2019-03-25 | Janssen Vaccines & Prevention Bv | Vaccine against rsv |
EP3142750B1 (en) * | 2014-05-13 | 2020-07-01 | The Trustees Of The University Of Pennsylvania | Compositions comprising aav expressing dual antibody constructs and uses thereof |
JP6735288B2 (ja) | 2015-04-14 | 2020-08-05 | ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. | 双方向性プロモーターを有する2つの導入遺伝子を発現する組換えアデノウイルス |
-
2017
- 2017-05-11 CA CA3023322A patent/CA3023322A1/en active Pending
- 2017-05-11 ES ES17725200T patent/ES2829272T3/es active Active
- 2017-05-11 CN CN201780029284.9A patent/CN109154000B/zh active Active
- 2017-05-11 BR BR112018072865-9A patent/BR112018072865A2/pt active Search and Examination
- 2017-05-11 MX MX2018013817A patent/MX2018013817A/es unknown
- 2017-05-11 EP EP17725200.4A patent/EP3455358B1/en active Active
- 2017-05-11 JP JP2018559728A patent/JP7046835B2/ja active Active
- 2017-05-11 KR KR1020187032966A patent/KR102573534B1/ko active IP Right Grant
- 2017-05-11 US US16/301,013 patent/US11473105B2/en active Active
- 2017-05-11 RU RU2018143810A patent/RU2758238C2/ru active
- 2017-05-11 WO PCT/EP2017/061282 patent/WO2017194655A1/en unknown
- 2017-05-11 AU AU2017264562A patent/AU2017264562B2/en active Active
-
2018
- 2018-11-08 IL IL262876A patent/IL262876A/en unknown
- 2018-11-09 ZA ZA2018/07542A patent/ZA201807542B/en unknown
-
2022
- 2022-09-07 US US17/930,158 patent/US20230279425A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20230279425A1 (en) | 2023-09-07 |
AU2017264562A1 (en) | 2018-11-01 |
KR102573534B1 (ko) | 2023-08-31 |
CA3023322A1 (en) | 2017-11-16 |
BR112018072865A2 (pt) | 2019-04-30 |
CN109154000B (zh) | 2022-07-05 |
RU2758238C2 (ru) | 2021-10-26 |
EP3455358B1 (en) | 2020-08-26 |
US11473105B2 (en) | 2022-10-18 |
ZA201807542B (en) | 2021-05-26 |
US20190264225A1 (en) | 2019-08-29 |
KR20190008229A (ko) | 2019-01-23 |
EP3455358A1 (en) | 2019-03-20 |
WO2017194655A1 (en) | 2017-11-16 |
JP2019514415A (ja) | 2019-06-06 |
IL262876A (en) | 2018-12-31 |
MX2018013817A (es) | 2019-03-21 |
AU2017264562B2 (en) | 2023-03-09 |
ES2829272T3 (es) | 2021-05-31 |
CN109154000A (zh) | 2019-01-04 |
RU2018143810A (ru) | 2020-06-15 |
JP7046835B2 (ja) | 2022-04-04 |